A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Moderate and Severe Plaque Psoriasis

In brief

This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease severity such that systemic treatment is justified). The treatment free Follow-up Period is designed to provide additional safety data and information on disease recurrence after the last dose of the study drug.

Key facts

Study ID

NCT00885196

Run by

Novartis Pharmaceuticals

People needed

336

Starts

2009-04-01

Last updated by the study team

2020-12-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate and Severe Plaque psoriasis diagnosed for at least 12 months (with or without psoriatic arthritis as comorbidity)that requires systemic therapy
• Severity of disease meeting all of the following three criteria:
• PASI score of 10 or greater
• Total Body Surface Area (BSA) affected by plaque psoriasis of 10% or greater
• Investigator's Global Assessment (IGA) score of 3 or greater

You may not qualify if…

• Hematological abnormalities
• Heart rate < 50 or > 90 bpm when resting for 5 minutes
• Family history of long QT syndrome
• History of tachyarrhythmia
• History of conduction abnormality i.e., PR > 200 msec, 2nd or 3rd degree AV block, complete left or right branch bundle block, pre-excitation syndrome
• Uncontrolled or unstable angina pectoris; history of myocardial infarction within the previous 12 months
• Known history of congestive heart failure
• History of percutaneous coronary intervention (PCI) or cardiac ablation
• History of stroke or transient ischemic attack (TIA)
• Implanted cardiac pacemaker or defibrillator
• History of malignancy of any organ system
• Current guttate, generalized erythrodermic, or pustular psoriasis
• Current drug associated psoriasis
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Burke Pharmaceutical Research — Hot Springs, Arizona, United States
• Belleair Research Center, LLC — Pinellas Park, Florida, United States
• Kansas City Dermatology, PA — Overland Park, Kansas, United States
• Dermatology Specialists — Louisville, Kentucky, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Central Dermatology — St Louis, Missouri, United States
• Palmetto Clinical Trial Services — Greenville, South Carolina, United States
• Center for Clinical Studies — Houston, Texas, United States
• Suzanne Bruce & Associates, PA — Houston, Texas, United States
• Virginia Clinical Research — Norfolk, Virginia, United States
• Novartis Investigative site — Buenos Aires, Argentina
• Novartis Investigative site — Mendoza, Argentina
• Novartis Investigative site — Benowa, Australia
• Novartis Investigative site — Carlton, Australia
• Novartis Investigative site — Kogarah, Australia
• Novartis Investigative site — Parkville, Australia
• Novartis Investigative site — Brussels, Belgium
• Novartis Investigative site — Edegem, Belgium
• Novartis Investigative site — Liège, Belgium
• Novartis Investigative site — Berlin, Germany
• Novartis Investigative site — Bonn, Germany
• Novartis Investigative site — Erlangen, Germany
• Novartis Investigative site — Frankfurt, Germany
• Novartis Investigative site — Hamburg, Germany
• Novartis Investigative site — Kiel, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.